FOXO4-DRI Research Guide (Preclinical Overview)
FOXO4-DRI is a specialized cell-penetrating peptide designed to selectively disrupt the interaction between Forkhead box O4 (FOXO4) and the tumor suppressor protein p53. Developed for in vitro and preclinical investigation, this retro-inverso peptide serves as a primary tool for probing targeted apoptosis pathways in senescent cell populations. Supplied strictly for laboratory research use only, FOXO4-DRI provides insights into cellular aging mechanisms, senescent cell clearance, and tissue homeostasis.
Quick answer
FOXO4-DRI is a specialized cell-penetrating peptide designed to selectively disrupt the interaction between Forkhead box O4 (FOXO4) and the tumor suppressor protein p53. Developed for in vitro and preclinical investigation, this retro-inverso peptide serves as a primary tool for probing targeted apoptosis pathways in senescent cell populations. Supplied strictly for laboratory research use only, FOXO4-DRI provides insights into cellular aging mechanisms, senescent cell clearance, and tissue homeostasis.
Key takeaways
- Cellular senescence is characterized by irreversible cell cycle arrest, metabolic altered states, and the secretion of a proinflammatory milieu known as the senescence-associated secretory phenotype (SASP).
- The molecular structure of FOXO4-DRI incorporates a specialized chemical modification known as a D-retro-inverso (DRI) peptide design.
- In non-senescent cells, the p53 protein functions as a critical regulator of cellular stress, dictating whether a cell undergoes DNA repair, cell cycle arrest, or programmed cell death (apoptosis).
- A critical focus of current [preclinical research](/research) is establishing the high degree of cell-type selectivity displayed by FOXO4-DRI.
Introduction to FOXO4-DRI in Preclinical Science
Cellular senescence is characterized by irreversible cell cycle arrest, metabolic altered states, and the secretion of a proinflammatory milieu known as the senescence-associated secretory phenotype (SASP). While senescence serves as an vital tumor suppressor mechanism during early tissue damage, the accumulation of senescent cells over time contributes to chronic tissue dysfunction in preclinical aging models. Investigating selective methods to eliminate these dysfunctional cells—a strategy known as senolysis—has become a cornerstone of geroscience research.
FOXO4-DRI emerged as a novel peptide designed to target a specific molecular checkpoint that maintains senescent cell survival. Unlike broad-spectrum cytotoxic agents, FOXO4-DRI targets the altered signaling landscape unique to senescent cells. Researchers utilize this compound within research peptides literature to study how disrupting intracellular protein-protein interactions can restore native apoptotic pathways in dysfunctional cells.
Molecular Architecture: The D-Retro-Inverso Strategy
The molecular structure of FOXO4-DRI incorporates a specialized chemical modification known as a D-retro-inverso (DRI) peptide design. Standard L-amino acid peptides are highly susceptible to rapid enzymatic degradation by endogenous proteases in culture media and tissue models. To overcome this kinetic limitation, synthesized D-amino acids are arranged in reverse sequence order relative to the native L-peptide sequence.
This structural inversion preserves the side-chain spatial topography necessary for selective target binding while altering the peptide backbone geometry. As a result, proteolytic enzymes fail to recognize the D-peptide bonds, significantly enhancing peptide half-life during in vitro assays and animal models. Synthesized using high-precision solid-phase peptide synthesis (SPPS), FOXO4-DRI demonstrates extended stability in experimental environments, allowing researchers to evaluate sustained biological signaling without rapid degradation.
Mechanism of Action: Target Disruption of FOXO4-p53 Axis
In non-senescent cells, the p53 protein functions as a critical regulator of cellular stress, dictating whether a cell undergoes DNA repair, cell cycle arrest, or programmed cell death (apoptosis). In senescent cell populations, overexpressed FOXO4 transcription factor physically sequesters phosphorylated p53 within the cell nucleus. This sequestration prevents p53 from translocating to the mitochondria or activating pro-apoptotic transcription factors, effectively granting senescent cells resistance against intrinsic apoptosis.
Preclinical studies suggest that FOXO4-DRI acts as a competitive antagonist against this interaction. By mimicking the FOXO4 binding domain that interacts with p53, the synthetic peptide selectively competes for p53 binding. Upon displacement from FOXO4, p53 is released to translocate to the outer mitochondrial membrane or interact with downstream effectors, triggering outer mitochondrial membrane permeabilization, cytochrome c release, and activation of caspase-3 and caspase-7 dependent apoptotic pathways.
Cellular Selectivity and Preclinical Model Evidence
A critical focus of current preclinical research is establishing the high degree of cell-type selectivity displayed by FOXO4-DRI. In vitro data indicate that high FOXO4 expressions are unique to senescent cell phenotypes, whereas healthy control cells maintain baseline levels of FOXO4 and low rates of p53 sequestration. Consequently, administration of FOXO4-DRI in cell culture models induces apoptosis selectively in senescent fibroblasts and endothelial cells while leaving non-senescent surrounding cells unharmed.
In rodent models of accelerated aging and tissue damage, preclinical administration of FOXO4-DRI demonstrated measurable reductions in senescent cell markers, such as p16INK4a, p21, and senescence-associated beta-galactosidase (SA-beta-gal). Furthermore, these studies observed reductions in systemic circulating SASP factors, including interleukin-6 (IL-6) and matrix metalloproteinases (MMPs). These outcomes highlight the compound's utility as a targeted molecular probe in cellular senescence studies.
Comparative Analysis: FOXO4-DRI vs. Related Cellular Target Compounds
When designing preclinical protocols focused on cellular homeostasis and metabolic integrity, investigators frequently compare FOXO4-DRI with other target-specific research compounds. While FOXO4-DRI functions strictly through nuclear protein-protein interaction disruption to induce senolysis, compounds such as epithalon operate primarily through telomerase activation mechanisms and gene expression modulation. Similarly, mitochondrial-targeted peptides offer alternative pathways for evaluating cellular stress responses.
For example, researchers investigating mitochondrial energetics and oxidative stress dynamics often utilize ss-31 to stabilize cardiolipin in the inner mitochondrial membrane, or mots-c to examine nuclear-mitochondrial metabolic signaling. While mitochondrial protectants focus on preserving organelle function under metabolic strain, FOXO4-DRI provides a mechanism for clearing cells that have passed the threshold of functional recovery. Evaluating these distinct pathways within the same laboratory platform allows for comprehensive mapping of cell survival versus apoptotic signaling.
Laboratory Handling, Reconstitution, and Storage Protocols
FOXO4-DRI is supplied as a lyophilized powder for laboratory research use only. To maintain peptide integrity, lyophilized vials should be stored at -20°C or -80°C away from direct light upon receipt. Prior to reconstitution, vials should be allowed to equilibrate to room temperature inside a desiccated chamber to prevent moisture condensation on the lyophilized cake.
Reconstitution protocols require sterile, laboratory-grade solvents. Depending on assay requirements, researchers typically solubilize FOXO4-DRI in sterile bacteriostatic water, phosphate-buffered saline (PBS), or dimethyl sulfoxide (DMSO) according to specific solubility thresholds. For detailed reconstitution guidelines across various peptide configurations, consult our comprehensive peptide solubility guide. Once reconstituted, aliquots should be prepared to avoid freeze-thaw cycles, which can destabilize secondary peptide structures.
Quality Assurance: HPLC, MS, and Analytical Rigor
In vitro and animal models require high-purity research materials to ensure that observed bioactivity is attributable solely to the target sequence rather than synthesis artifacts or truncated peptide contaminants. Because retro-inverso sequences contain D-amino acid stereocenters, stringent analytical verification is essential during quality control.
Every lot of synthesized peptide offered by PX1 Research undergoes rigorous verification, including High-Performance Liquid Chromatography (HPLC) to establish purity levels exceeding 98%, and Electrospray Ionization Mass Spectrometry (ESI-MS) to verify precise molecular mass. In addition, mandatory testing ensures that endotoxin levels remain strictly below <0.1 EU/mg, protecting cell culture assays from unwanted lipopolysaccharide-induced inflammatory artifacts. For further details on our testing benchmarks, review our peptide purity standards technical page.
Designing Experimental Assays with FOXO4-DRI
Researchers incorporating foxo4-dri into experimental workflows must consider several variables, including induction method of senescence (e.g., ionizing radiation, replicative exhaustion, or doxorubicin treatment), incubation duration, and target concentration ranges. Common readout assays involve measuring Annexin V/PI staining via flow cytometry to quantify early and late apoptosis rates across cell populations.
Supplementary assays often quantify changes in nuclear translocation of p53 using high-content fluorescence microscopy, alongside Western blot analysis for cleaved caspase-3 and PARP cleavage. Establishing appropriate vehicle controls and negative control peptides (such as mutated non-binding sequence analogs) is critical for isolating the specific competitive inhibition mechanism of the FOXO4-p53 interaction domain.
Sourcing Research-Grade FOXO4-DRI from PX1 Research
Obtaining reliable, highly pure materials is fundamental to reproducing complex cell signaling data. PX1 Research synthesizes all compounds within state-of-the-art, ISO 17025 accredited and GMP-compliant facilities located in the United States. Each product lot is accompanied by a third-party Certificate of Analysis (COA) confirming identity, purity, and endotoxin metrics.
To accommodate various project scales, researchers can access individual units or establish bulk purchasing arrangements via our wholesale lab account portal. Orders are fulfilled directly from our modern distribution centers in California and Arizona, offering same-day dispatch for orders placed Monday through Friday prior to cutoff times.
Frequently Asked Questions
What is the specific sequence configuration of FOXO4-DRI?
FOXO4-DRI is a D-retro-inverso peptide synthesized using D-amino acids in the reverse sequence of the native FOXO4 interaction domain with p53. This modification provides enhanced resistance to proteolytic breakdown while retaining binding affinity for the target p53 sequence.
How does FOXO4-DRI induce apoptosis specifically in senescent cells?
Preclinical studies suggest that FOXO4-DRI disrupts the physical binding between FOXO4 and p53, which is upregulated in senescent cells. Releasing p53 allows it to translocate to mitochondria and trigger the intrinsic apoptotic pathway (via caspase activation) in senescent cells, while sparing non-senescent cells expressing baseline FOXO4.
What solvents are recommended for reconstituting FOXO4-DRI for in vitro work?
FOXO4-DRI is typically reconstituted using sterile PBS, sterile water for injection, or dimethyl sulfoxide (DMSO) depending on the stock concentration required for the assay. Researchers should consult lot-specific solubility documentation before preparing working solutions.
What endotoxin levels are verified for PX1 Research peptides?
All peptides supplied by PX1 Research undergo quantitative chromogenic LAL assays to confirm that endotoxin levels are below 0.1 EU/mg, preventing cell culture contamination or nonspecific immune activation in preclinical models.
How should reconstituted FOXO4-DRI solutions be stored in the laboratory?
Reconstituted liquid solutions should be divided into single-use aliquots and stored at -20°C or -80°C to maintain stability. Repeated freeze-thaw cycles should be avoided as they degrade peptide structure.
What analytical methods are used to verify the purity of FOXO4-DRI?
PX1 Research utilizes High-Performance Liquid Chromatography (HPLC) to verify chromatographic purity (typically ≥98%) and Mass Spectrometry (MS) to confirm exact molecular mass and sequence fidelity.
Can FOXO4-DRI be evaluated in combination with mitochondrial peptides?
Yes, researchers frequently structure comparative or combination preclinical models evaluating FOXO4-DRI alongside mitochondrial compounds like SS-31 or MOTS-c to study the dual interplay of cell clearance and organelle preservation.
Where are PX1 Research peptides synthesized and shipped from?
All PX1 Research peptides are USA-synthesized in ISO 17025 accredited, GMP-compliant facilities and shipped directly from fulfillment centers in California and Arizona with same-day shipping available Monday through Friday.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.